Cyclin A/B RxL macrocyclic inhibitors to treat cancers with high E2F activity by Singh, S, Gleason, CE, Fang, M, Laimon, YN, Khivansara, V, Xie, S, Durmaz, YT, Sarkar, A, Ngo, K, Savla, V, Li, Y, Abu-Remaileh, M, Li, X, Tuladhar, B, Odeh, R, Hamkins-Indik, F, He, D, Membreno, MW, Nosrati, M, Gushwa, NN, Leung, SSF, Fraga-Walton, B, Hernandez, L, Baldomero, MP, Lent, BM, Spellmeyer, D, Luna, JF, Hoang, D, Gritsenko, Y, Chand, M, DeMart, MK, Metobo, S, Bhatt, C, Shapiro, JA, Yang, K, Dupper, NJ, Bockus, AT, Doench, JG, Aggen, JB, Liu, L-F, Levin, B, Wang, EW, Vendrell, I, Fischer, R, Kessler, B, Gokhale, PC, Signoretti, S, Spektor, A, Kreatsoulas, C, Singh, R, Earp, DJ, Garcia, PD, Nijhawan, D, Oser, MG